|
Incidence of any infections and SARS-CoV-2 infections in patients receiving treatment for follicular lymphoma and diffuse large B-cell lymphoma: Real-world evidence from a large US national claims database. |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
| |
|
|
Stock and Other Ownership Interests - Regeneron |
Patents, Royalties, Other Intellectual Property - Odronextamab related patents |